US 12110504
Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes
granted A61KA61K48/0058A61K48/0075
Quick answer
US patent 12110504 (Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes) held by United States Government as represented by the Department of Veterans Affairs expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- United States Government as represented by the Department of Veterans Affairs
- Grant date
- Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 23
- CPC classes
- A61K, A61K48/0058, A61K48/0075, A61K48/0091, A61P